Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.32 |
| ▸ | BRAF | P15056 | 5/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966695 | 1.00 | PPARG (0.37) | PPARGMTNR1AENPP3ENPP1BRAF | |
| SCHEMBL963474 | 0.85 | MTNR1A (0.35) | PPARGMTNR1AENPP3ENPP1BRAF | |
| SCHEMBL963473 | 0.85 | MTNR1A (0.35) | PPARGMTNR1AENPP3ENPP1BRAF | |
| SCHEMBL962976 | 0.79 | MTNR1A (0.40) | MTNR1AENPP3ENPP1 | |
| SCHEMBL962978 | 0.79 | MTNR1A (0.40) | MTNR1AENPP3ENPP1 | |
| SCHEMBL963804 | 0.78 | MTNR1A (0.38) | MTNR1A | |
| SCHEMBL963808 | 0.76 | PPARG (0.39) | PPARGMTNR1AENPP1CNR2CNR1 | |
| SCHEMBL966145 | 0.74 | PPARG (0.38) | PPARGMTNR1AENPP3ENPP1BRAF | |
| SCHEMBL963879 | 0.74 | PPARG (0.38) | PPARGMTNR1AENPP3ENPP1BRAF | |
| SCHEMBL964053 | 0.72 | PPARG (0.38) | PPARGMTNR1AENPP3BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | PPARG 248/4885MTNR1A 310/4885ENPP3 1924/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | PPARG 3/4885MTNR1A 69/4885ENPP3 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.